
GeneThera, Inc. Share · US37185E3062 (OTC) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of GeneThera, Inc.
No Price
Company Profile for GeneThera, Inc. Share
GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatments for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne's disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacterium avium sub paratuberculosis bacteria. The company's Molecular Robotic/AI Platform and Therapeutic strategy is designed to prevent the spread of disease from animals and allow to better control of zoonotic infectious agents. GeneThera, Inc. is based in Westminster, Colorado.
Company Data
Name GeneThera, Inc.
Company GeneThera, Inc.
Website
https://www.genethera.net
Primary Exchange
UTC
ISIN US37185E3062
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Antonio Milici
Country United States of America
Currency USD
Employees 0,0 T
Address 3051 West 105th Avenue, 80035 Westminster
IPO Date 2012-09-25
Dividends from 'GeneThera, Inc.'
| Ex-Date | Dividend per Share |
|---|---|
| 17.05.2007 | 0,0004 USD |
Stock Splits
| Date | Split |
|---|---|
| 09.07.2008 | 1:5000 |
| 03.09.2002 | 2:1 |
| 18.01.2002 | 1:8 |
Ticker Symbols
| Name | Symbol |
|---|---|
| Over The Counter | GTHR |
More Shares
Investors who hold GeneThera, Inc. also have the following shares in their portfolio:
